$NBIX
NEUROCRINE BIOSCIENCES INC

2014 Q3 Form 10-Q Financial Statement

#000119312514298386 Filed on August 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $0.00 $0.00 $730.0K
YoY Change -100.0% -100.0% -93.09%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.700M $4.200M $3.400M
YoY Change 46.88% 23.53% 9.68%
% of Gross Profit
Research & Development $12.19M $10.16M $10.53M
YoY Change 28.49% -3.48% 19.38%
% of Gross Profit
Depreciation & Amortization $200.0K $200.0K $100.0K
YoY Change 0.0% 100.0% 0.0%
% of Gross Profit
Operating Expenses $16.86M $14.36M $13.90M
YoY Change 32.37% 3.34% 16.3%
Operating Profit -$16.86M -$14.36M -$13.17M
YoY Change 40.4% 9.07% 854.13%
Interest Expense $200.0K $200.0K $100.0K
YoY Change 100.0% 100.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $982.0K $980.0K $925.0K
YoY Change 12.23% 5.95% 5.23%
Pretax Income -$15.90M -$13.40M -$12.20M
YoY Change 43.24% 9.84% 2340.0%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$15.88M -$13.38M -$12.24M
YoY Change 42.62% 9.3% 2343.51%
Net Earnings / Revenue -1676.99%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$209.5K -$176.5K -$0.18
COMMON SHARES
Basic Shares Outstanding 75.92M shares 75.86M shares 66.80M shares
Diluted Shares Outstanding 66.80M shares

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $179.7M $194.7M $153.7M
YoY Change 14.53% 26.68% -13.41%
Cash & Equivalents $29.05M $37.45M $44.31M
Short-Term Investments $150.6M $157.2M $109.4M
Other Short-Term Assets $4.194M $2.119M
YoY Change 87.9% -2.75%
Inventory
Prepaid Expenses
Receivables $2.900M $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $183.9M $197.6M $155.9M
YoY Change 15.48% 26.77% -14.02%
LONG-TERM ASSETS
Property, Plant & Equipment $2.292M $2.239M $1.876M
YoY Change 31.8% 19.35% 0.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $67.10M $65.30M $12.70M
YoY Change 9485.71% 414.17% -13.01%
Other Assets $4.400M $4.400M $4.300M
YoY Change 2.33% 2.33% 0.0%
Total Long-Term Assets $73.88M $71.96M $18.96M
YoY Change 994.73% 279.56% -8.97%
TOTAL ASSETS
Total Short-Term Assets $183.9M $197.6M $155.9M
Total Long-Term Assets $73.88M $71.96M $18.96M
Total Assets $257.8M $269.5M $174.8M
YoY Change 55.3% 54.19% -13.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $900.0K $846.0K $1.348M
YoY Change -17.96% -37.24% -5.07%
Accrued Expenses $9.307M $7.439M $8.185M
YoY Change 18.08% -9.11% 17.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.05M $12.05M $14.57M
YoY Change 5.44% -17.29% -50.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $260.0K $260.0K $152.0K
YoY Change 71.05% 71.05% 0.66%
Total Long-Term Liabilities $260.0K $260.0K $152.0K
YoY Change 71.05% 71.05% 0.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.05M $12.05M $14.57M
Total Long-Term Liabilities $260.0K $260.0K $152.0K
Total Liabilities $33.71M $32.69M $38.80M
YoY Change -8.07% -15.73% -32.36%
SHAREHOLDERS EQUITY
Retained Earnings -$806.9M -$791.0M -$744.0M
YoY Change 6.85% 6.32% 2.47%
Common Stock $76.00K $76.00K $67.00K
YoY Change 13.43% 13.43% 1.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $224.0M $236.8M $136.0M
YoY Change
Total Liabilities & Shareholders Equity $257.8M $269.5M $174.8M
YoY Change 55.3% 54.19% -13.5%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$15.88M -$13.38M -$12.24M
YoY Change 42.62% 9.3% 2343.51%
Depreciation, Depletion And Amortization $200.0K $200.0K $100.0K
YoY Change 0.0% 100.0% 0.0%
Cash From Operating Activities -$12.10M -$9.900M -$9.800M
YoY Change 12.04% 1.02% 42.03%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K -$600.0K -$200.0K
YoY Change 200.0% 200.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $3.500M -$57.70M $21.20M
YoY Change -391.67% -372.17% -175.99%
Cash From Investing Activities $3.200M -$58.40M $21.00M
YoY Change -346.15% -378.1% -174.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 500.0K 300.0K 1.600M
YoY Change -81.48% -81.25%
NET CHANGE
Cash From Operating Activities -12.10M -9.900M -9.800M
Cash From Investing Activities 3.200M -58.40M 21.00M
Cash From Financing Activities 500.0K 300.0K 1.600M
Net Change In Cash -8.400M -68.00M 12.80M
YoY Change -10.64% -631.25% -136.57%
FREE CASH FLOW
Cash From Operating Activities -$12.10M -$9.900M -$9.800M
Capital Expenditures -$300.0K -$600.0K -$200.0K
Free Cash Flow -$11.80M -$9.300M -$9.600M
YoY Change 10.28% -3.13% 43.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
75919404 shares
CY2013Q1 nbix Cease Use Liability
CeaseUseLiability
3492000
CY2014Q1 nbix Cease Use Liability
CeaseUseLiability
2994000
CY2013Q2 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
19300000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44313000
CY2013Q2 nbix Cease Use Liability
CeaseUseLiability
3295000
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75919009 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75919009 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
52000
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
12053000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
76000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-126000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
846000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-790986000
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7439000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
236845000
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
269539000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1027881000
CY2014Q2 us-gaap Liabilities
Liabilities
32694000
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1942000
CY2014Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
23000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37445000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2239000
CY2014Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
2919000
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
222493000
CY2014Q2 nbix Cease Use Liability
CeaseUseLiability
2892000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
172301000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4443000
CY2014Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
149000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2014Q2 us-gaap Long Term Investments
LongTermInvestments
65282000
CY2014Q2 us-gaap Assets
Assets
269539000
CY2014Q2 us-gaap Short Term Investments
ShortTermInvestments
157211000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
149000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
149000
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
222619000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2014Q2 us-gaap Assets Current
AssetsCurrent
197575000
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
172301000
CY2014Q2 us-gaap Investments
Investments
222500000
CY2014Q2 nbix Letters Of Credit Collateral
LettersOfCreditCollateral
4200000
CY2014Q2 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 RenewalOptions
CY2014Q2 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3275000
CY2014Q2 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2451000
CY2014Q2 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
441000
CY2014Q2 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
15988000
CY2008Q4 us-gaap Sale Leaseback Transaction Deferred Gain Net
SaleLeasebackTransactionDeferredGainNet
39100000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63754000
CY2012Q4 nbix Cease Use Liability
CeaseUseLiability
3686000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67351195 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67351195 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
110000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11699000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
101000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-765763000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7955000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
120410000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
154676000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
886101000
CY2013Q4 us-gaap Liabilities
Liabilities
34266000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1982000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44789000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1771000
CY2013Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
2723000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
100950000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
39721000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4443000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2013Q4 us-gaap Assets
Assets
154676000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
100950000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
15000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
15000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2013Q4 us-gaap Assets Current
AssetsCurrent
148462000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
39721000
CY2013Q4 us-gaap Investments
Investments
101000000
CY2013Q4 nbix Deferred Gain On Sale Of Real Estate Current
DeferredGainOnSaleOfRealEstateCurrent
3227000
CY2013Q4 nbix Cease Use Liability Noncurrent
CeaseUseLiabilityNoncurrent
2680000
CY2013Q4 nbix Cease Use Liability Current
CeaseUseLiabilityCurrent
416000
CY2013Q4 nbix Cease Use Liability
CeaseUseLiability
3096000
CY2013Q4 nbix Deferred Gain On Sale Of Real Estate Noncurrent
DeferredGainOnSaleOfRealEstateNoncurrent
17645000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
800000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2100000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7948000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66700000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
600000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
600000 shares
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-32000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1595000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1358000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
1600000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
95612000
us-gaap Licenses Revenue
LicensesRevenue
1460000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-14094000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26142000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
32000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24359000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1825000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
us-gaap Revenues
Revenues
1460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
323000
us-gaap Net Income Loss
NetIncomeLoss
-24317000
us-gaap Investment Income Net
InvestmentIncomeNet
224000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3400000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1460000
us-gaap Operating Expenses
OperatingExpenses
27602000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20840000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
76000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19441000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
347000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2591000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2591000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14084000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2600000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
81819000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6762000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
528000
us-gaap Share Based Compensation
ShareBasedCompensation
3412000
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
1563000
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-391000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
391000
us-gaap Property Management Fee Percent Fee
PropertyManagementFeePercentFee
0.035 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
900000 shares
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES INC
dei Trading Symbol
TradingSymbol
NBIX
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2800000 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19732000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <i>Use of Estimates</i>. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73085000 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
dei Entity Central Index Key
EntityCentralIndexKey
0000914475
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
208337000
us-gaap Licenses Revenue
LicensesRevenue
0
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
196000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27086000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25354000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
93000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500000 shares
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1604000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1594000
us-gaap Sale Leaseback Transaction Current Period Gain Recognized
SaleLeasebackTransactionCurrentPeriodGainRecognized
1600000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1863000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Revenues
Revenues
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
904000
us-gaap Net Income Loss
NetIncomeLoss
-25223000
us-gaap Investment Income Net
InvestmentIncomeNet
256000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-131000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5300000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Operating Expenses
OperatingExpenses
27086000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18733000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
12000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7344000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
386000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
136515000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
136515000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
45000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-124127000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3300000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
85069000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8353000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
229000
us-gaap Share Based Compensation
ShareBasedCompensation
5274000
nbix Lease Expiration Year
LeaseExpirationYear
2019
nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
1609000
nbix Lease Extension Period
LeaseExtensionPeriod
P10Y
nbix Increase Decrease In Cease Use Liability
IncreaseDecreaseInCeaseUseLiability
-204000
nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
204000
CY2014Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
17.75
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8000000 shares
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
133200000
CY2007Q4 us-gaap Mortgage Loans On Real Estate Cost Of Mortgages Sold
MortgageLoansOnRealEstateCostOfMortgagesSold
47700000
CY2007Q4 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
61000000
CY2007Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
109000000
CY2007Q4 nbix Number Of Buildings Leased
NumberOfBuildingsLeased
2 Building
CY2007Q4 nbix Sale Leaseback Transaction Lease Period
SaleLeasebackTransactionLeasePeriod
P12Y
CY2013Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2300000 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
66799000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
300000 shares
CY2013Q2 us-gaap Licenses Revenue
LicensesRevenue
730000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13167000
CY2013Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
19000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12242000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
925000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2013Q2 us-gaap Revenues
Revenues
730000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-12242000
CY2013Q2 us-gaap Investment Income Net
InvestmentIncomeNet
121000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1700000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
13897000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10527000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3370000
CY2013Q2 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
781000
CY2013Q2 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
197000
CY2014Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2600000 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75879000 shares
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10161000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4200000
CY2014Q2 nbix Deferred Gain On Sale Of Real Estate
DeferredGainOnSaleOfRealEstate
805000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
900000 shares
CY2014Q2 us-gaap Licenses Revenue
LicensesRevenue
0
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14361000
CY2014Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
5000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13313000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
980000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2014Q2 us-gaap Revenues
Revenues
0
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-13381000
CY2014Q2 us-gaap Investment Income Net
InvestmentIncomeNet
167000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
68000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2900000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
14361000
CY2014Q2 nbix Cease Use Liability Payment
CeaseUseLiabilityPayment
102000

Files In Submission

Name View Source Status
0001193125-14-298386-index-headers.html Edgar Link pending
0001193125-14-298386-index.html Edgar Link pending
0001193125-14-298386.txt Edgar Link pending
0001193125-14-298386-xbrl.zip Edgar Link pending
d738591d10q.htm Edgar Link pending
d738591dex101.htm Edgar Link pending
d738591dex311.htm Edgar Link pending
d738591dex312.htm Edgar Link pending
d738591dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nbix-20140630.xml Edgar Link completed
nbix-20140630.xsd Edgar Link pending
nbix-20140630_cal.xml Edgar Link unprocessable
nbix-20140630_def.xml Edgar Link unprocessable
nbix-20140630_lab.xml Edgar Link unprocessable
nbix-20140630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending